All In Biotech

Drug Trial Radar · NCT07455240

A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of PF-07328948 Following Multiple Oral Doses in Healthy Chinese Adult Participants

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Mar 2, 2026

Primary completion

Apr 15, 2026

Study completion Apr 15, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about: * How PF-07328948 is changed and removed from the body after taking * Safety of PF-07328948 * The extent to which undesirable effects can be tolerated after taking PF-07328948 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years old and older * Have body mass index from 18.5 to under 28 kilograms/meter square * Have a total body weight over 50 kilograms (110 pounds) * Do not have a history of blood clots blocking an artery or vein All participants in this study will receive oral daily PF-07328948 at the study clinic for 7 consecutive days. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 10 weeks. During this time, participants will have 1 study visit at the study clinical and 1 contact over the phone.

Conditions

  • Healthy Participant

Interventions

  • PF-07328948Drug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Day 1, 7
  2. Area under the plasma concentration (AUC)Time frame: Day 1, 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.